Fostamatinib, a Syk-Kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis

Journal of Clinical Pharmacology

Volumn 51, Issue 9, 2011, Pages 1310-1318

  Baluom, Muhammad ^a   Samara, Emil ^b   Grossbard, Elliott B ^a   Lau, David T W ^a  

^a RIGEL PHARMACEUTICALS INC   (United States)

^b PharmaPolaris International Inc   (United States)

Author keywords

7 hydroxymethotrexate; Fostamatinib; methotrexate; pharmacokinetics; rheumatoid arthritis

Indexed keywords

7 HYDROXYMETHOTREXATE; ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; FOSTAMATINIB; METHOTREXATE; PLACEBO; PREDNISONE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPHIL COUNT; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SOMNOLENCE; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; METHOTREXATE; MIDDLE AGED; OXAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES;

EID: 80051779551     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010381496     Document Type: Article

References (27)

1. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase SYK: essential functions for immunoreceptor signaling. Immunol Today. 2000 ; 21: 148-154 (Pubitemid 30122705)
2. Berton G, Mocsai A, Lowell CA. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol. 2005 ; 26: 208-214 (Pubitemid 41556858)
3. Nimmerjahn F, Ravetch JV. Fc receptors: old friends and new family members. Immunity. 2006 ; 24: 19-28 (Pubitemid 43077197)
4. Singh R, Masuda ES. Spleen tyrosine kinase (SYK) biology, inhibitors and therapeutic applications. Ann Rep Med Chem. 2007 ; 42: 379-391
5. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs. 2004 ; 13: 743-762 (Pubitemid 39028928)
6. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003 ; 21 (suppl 31). S179 - S185
7. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 ; 319: 998-1008
8. Pine PR, Chang B, Schoettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007 ; 124: 244-257 (Pubitemid 47247604)
9. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a SYK kinase inhibitor: a twelve week, randomized, placebo-controlled trial. Arthritis Rheum. 2008 ; 58: 3309-3318
10. Weinblatt M, Kavanaugh A, Genovese M, Kane Musser T, Grossbard E, Magilavy D. An oral spleen tyrosine kinase inhibitor for rheumatoid arthritis. N Engl J Med. :
11. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for the treatment of immune thrombocytopenic purpura by and inhibitor of Syk. Blood. 2009 ; 113: 3133-3134
12. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib Disodium has significant clinical activity in non Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 ; 115: 2561-2562
13. Chládek J, Martínková J, Sispera L. An in vitro study on methotrexate hydroxylation in rat and human liver. Physiol Res. 1997 ; 46: 371-379 (Pubitemid 27471204)
14. Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1993 ; 35: 409-412 (Pubitemid 23103382)
15. Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-Hydro-xymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest. 1976 ; 57: 534-538
16. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol. 1995 ; 22: 2072-2077
17. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet. 1986 ; 1: 256-258 (Pubitemid 16132863)
18. Sweeny DJ, Li W, Clough J, et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos. 2010 ; 38: 1166-1176
19. Sweeny DJ, Li W, Grossbard E, Lau DT. Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey. Xenobiotica. 2010 ; 40: 415-423
20. Steinborner S, Henion J. Liquid-liquid extraction in the 96-well plate format with SRM LC/MS quantitative determination of methotrexate and its major metabolite in human plasma. Anal Chem. 1999 ; 71: 2340-2345 (Pubitemid 29307595)
21. Cohen S, Zwillich SH, Chow V, Labadie RR, Wilkinson B. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol. 2010 ; 69: 143-51
22. Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum. 1991 ; 34: 1514-1520
23. Cassano WF. Serious methotrexate toxicity caused by inter-action with ibuprofen. Am J Pediatr Hematol Oncol. 1989 ; 11: 481-482 (Pubitemid 20020010)
24. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. Lancet. 1986 ; 1: 1390 (Pubitemid 16121926)
25. Schwartz JI, Agrawal NG, Wong PH, et al. Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J Clin Pharmacol. 2001 ; 41: 1120-1130 (Pubitemid 32880141)
26. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclo-oxygenase-2-selective inhibition. Am J. Med. 1999 ; 107 (suppl 1). 65S - 71S (Pubitemid 30042897)
27. Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 ; 302: 666-671 (Pubitemid 34787234)